Device-based therapies can provide considerable value for heart failure patients when used alongside traditional pharmaceutical treatments. A new HFSA scientific statement outlines the benefits of these devices, urging care teams to implement them into daily practice.
Today's heart teams already face a number of challenges on a day-to-day basis. New data suggest they could soon be treating more patients than ever before.
The show will go on. After HFSA was forced to cancel its annual meeting due to Hurricane Helene, the group will now be livestreaming a series of late-breaking clinical sessions for anyone who had previously registered.
The news comes just one day before HFSA 2024 was scheduled to begin. HFSA is already considering the possibility of virtual sessions, but its primary concern is the safety of attendees.
In addition to more traditional presentations, this year's meeting will also include "Rapid Fire" sessions designed to pack a lot of late-breaking data into a relatively small amount of time.
Leaders from the American Heart Association, American College of Cardiology, Heart Failure Society of America, Heart Rhythm Society and Society for Cardiovascular Angiography & Interventions have shared their vision for a new, independent Board of Cardiovascular Medicine.
The company can now begin the enrollment process for its PROACTIVE-HF 2 clinical trial, which will focus on treating patients with NYHA class II heart failure.
The subcutaneous administration of CBD could make a significant impact on patient outcomes, according to new findings presented at the Heart Failure Society of America's annual meeting in Cleveland.
American College of Cardiology President B. Hadley Wilson, MD, discussed why the ACC and other leading cardiology groups are so eager to create a new, independent medical board. This has been a long-term goal for many years, he said, and now it may become a reality.
"We know that the cardiovascular community is ready for an independent, self-governed entity, and we are proud to develop this new board with cardiologists and cardiology organizations at the helm," ACC President B. Hadley Wilson, MD, said in a statement.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
